Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2005-04-18
2008-12-09
Haddad, Maher M (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S152100, C530S388220
Reexamination Certificate
active
07462353
ABSTRACT:
A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1.
REFERENCES:
patent: 4683195 (1987-07-01), Mullis et al.
patent: 5391481 (1995-02-01), Chess et al.
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5648260 (1997-07-01), Winter et al.
patent: 5733743 (1998-03-01), Johnson et al.
patent: 5788966 (1998-08-01), Chess et al.
patent: 5789650 (1998-08-01), Lonberg et al.
patent: 5798230 (1998-08-01), Bornkamm et al.
patent: 5827690 (1998-10-01), Meade et al.
patent: 5855888 (1999-01-01), Nishida et al.
patent: 6001961 (1999-12-01), Jonczyk et al.
patent: 6016159 (2000-01-01), Faris
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6127524 (2000-10-01), Casipit et al.
patent: 6150584 (2000-11-01), Kucherlapati et al.
patent: 6162963 (2000-12-01), Kucherlapati et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6291650 (2001-09-01), Winter et al.
patent: 6300064 (2001-10-01), Knappik et al.
patent: 6303313 (2001-10-01), Wigler et al.
patent: 6307026 (2001-10-01), King et al.
patent: 6326403 (2001-12-01), Holzemann et al.
patent: 6632927 (2003-10-01), Adair et al.
patent: 0 239 400 (1987-09-01), None
patent: 0239400 (1997-09-01), None
patent: 0 843 961 (1998-05-01), None
patent: 08-131185 (1996-05-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO 99/61040 (1999-12-01), None
patent: WO 00/20459 (2000-04-01), None
patent: WO 00/72881 (2000-12-01), None
patent: WO 01/73444 (2001-10-01), None
patent: WO 01/96365 (2001-12-01), None
Briesewitz, et al., 1993, Journal of Biological Chemistry, 268:2989-2996. “Expression of Native and Truncated Forms of the Human Integrin al Subunit”.
Fabbri et al. 1996. Tissue Antigens. 48:47-51. “A functional monoclonal antibody recognizing the human alpha1-integrin 1-domain”.
Gotwals. et al. 1999, Biochemistry 38:8280-8288. “Divalent Cations Stabilize the alb1 Integrin I Domain”.
Kern et al., 1994. Journal of Biological Chemistry, 269:22811-22816. “The Role of the I Domain in Ligand Binding of the Human Integrin alb1”.
Laffon et al. 1989 Arthritis and Rheumatism 32:386-392. “Very Late Activation Antigen of Synovial Fluid T cells from Patients with Rheumatoid Arthritis and other Rheumatic Diseases”.
Baldwin et al., 1998, Structure, 6:923-935, “Cation binding to the integrin CD11b I domain and activation model assessment”.
Bennett et al., 1983, Proc. Natl. Acad. Sci., 80;2417-2421, “Inhibition of fibrinogen binding to stimulated human platelets by a monoclonal antibody”.
Boerner et al., 1991, J. Immunol., 147:86-95, “Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes”.
Border et al., 1994, New England J. Medicine, 331:1286-1292, “Transforming Growth Factor Beta In Tissue Fibrosis”.
Bossy et al., 1991, Embo J. , 10:2375-2385, “Characterization of the Integrin Alpha8 subnit: A new intefrin beta1-associated subunit, which is prominently expressed on axons and on cells in contact with basal laminae in chick embryos”.
Briesewitz et al., 1993, J. of Biol. Chemistry, 268:2989-2996, “Expression of Native and Truncated Forms of the human Integrin Alpha1 1 subunit”.
Bridges et al., 1995, Mol. Immunol., 32:1329-2989, “Variable Region cDNA Sequences and Characterization of Murine Anti-Human Inteferon y Receptor Monoclonal Antibodies that Inhibit Receptor Binding By Interferon y”.
Camper et al., 1998, J. Biol. Chem., 273:20383-20389, “Isolation, Cloning, and Sequence Analysis of the Integrin Subunit a10, a Beta1-associated Collagen Binding Integrin Expressed on Chondrocytes”.
Cerf-Bensussan et al., 1992, Eur. J. Immunol. 22:273-277, “The human intraepithelial lymphocyte marker HML-1 is an Integrin consisting of a Beta7 subunit associated with a distinctive alpha chain”.
Clackson et al., 1991, Nature, 352:624-628, “Making antibody fragments using phage display libraries”.
Co et al., 1991, Proc. Natl Acad. Sci., 88:2869-2873, “Humanized anotbodies for antiviral therapy”.
Colbert et al, 1991, J. of Immunol. Methods; 140: 227-233, “The effect of fluorescein labels on the affinity of antisera to small haptens”.
Corbi and Miller et al., 1987, J. of Biol. Chem., 263: 12403-12411, “cDNA cloning and complete primary struction fo the alpha subunit of a leukocyte adhesion glycoprotein, p150,95”.
Corbi and Kishimoto et al., 1988, J. of Biol. Chem., 263: 12403-12411, “The Human Leukocyte Adhesion Glycoprotein Mac-1 (Complement Receptor Type 3, CD11b) alpha Subunit”.
Davies, 1989, J. of Cell Biology, 109: 1817-1826, “The Osteoclast Functional Antigen, Implicated in the Regulation of Bone Resorption, Is Biochemically Related to the Vitronectin Receptor”.
Diamond et al., 1993, 120: 1031-1043, “The I Domain Is a Major Recognition Site on the Luekocyte Integrin Mac-1 (CD-11b/CD18) For Four Distinct Adhesion Ligands”.
Edwards et al., 1995, 270:12635-12640, “Identification of Amino Acids in the CD11a I-domain Important for Binding of the Leukocyte Function-associated Antigen-1 (LFA-1) to Intercellular Adhesion Molecules-1 (ICAM-1)”.
Gotwals et al., 1996, J. Clin. Invets., 97:2469-2477, “Thealpha1beta1 Integrin is expressed during Neointima Formation in Rat Arteries and Mediates Collagen Matrix Reorganization”.
Grayson et al., 1998, J. Exp. Med., 188:2187-2191, “alphadbeta2 Integrin Is Expressed on Human Eosinophils and Functions as an Alternative Ligand for Vascular Cell Adhesion Molecule 1 (VCAM-1)”.
Hemler et al., 1984, J. of Immunol., 132:3011-3018, “Glycoproteins of 210,000 and 130,000 M.W. On Activated T Cells: Cell Distribution And Antigenic Relation To Components On Resting Cells And T Cell Lines”.
Hemler et al., 1987, J. of Immunol., 262:11478-11485, “Characterization of the Cell Surface Heterodimer VLA-4 and Related Peptides”.
Hessle et al., 1984, Differentiation, 26:49-54, “Basement membrane diversity detected by monoclonal antibodies”.
Ignatius et al., 1990, J. of Cell Biology, 111:709-720, “Molecular Cloning of the Rat Integrin alpha1 Subunit: A Receptor for Laminin and Collagen”.
Kamata et al., 1995, J. of Biological Chem., 270:12531-12535, “Critical Threonine and Aspartic Acid Residues within the I Domains of beta2 Integrins for Interactions with Intercellular Adhesion Molecular 1 (ICAM-1) and C3bi”.
Keely et al., 1995, J. of Cell Science, 108:595-607, “Alteration of collagen-dependent adhesion, motility, and morphogenesis by the expression of antisense alpha 2 integrin mRNA in mammary cells”.
Kern et al., 1994, J. of Biol. Chem., 269:22811-55816, “The Role of the I Domain in Ligand Binding of the Human Integrin alpha1beta1”.
Langholz et al., 1995, J. of Cell Biol., 131:1903-1915, “Collagen and Collagenase Gene Expression in Three-dimensional Collagen Lattices Are Differentially Regulated by alpha1beta1 and alpha2beta1 Integrins”.
Larson et al., 1989, J. of Cell Biol., 108:703-712, “Primary Structure of the Leukocyte Function-associated Molecular-1 alpha Subunit: an Integrin with an Embedded Domain Defining a Protein Superfamily”.
Lee et al., 1995, Structure; 3:1333-1340, “Two conformations of the integrin A-domain (I-domain): a pathway for activation?”.
Lowry et al., 1951, Dept. of Pharma., Washington Univ. School of Med., 265-275, “Protein Measurement with the folin phenol reagent”.
Mendrick et al., 1995, Labratory Investigation, 72:367-375, “Glomerular Epithelial and Mesangial Cells Differentially Modulate the Binding Specificities of VLA-1 and VLA-2”.
Michishita et al., 1993, Cell Press, 72:857-867, “A Novel Divalent Catio
DeFougerolles Antonin
Gotwals Philip
Koteliansky Victor
Lobb Roy
Biogen Idec MA Inc.
Haddad Maher M
Lowrie, Lando & Anastasi
LandOfFree
Method for the treatment of inflammatory disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the treatment of inflammatory disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the treatment of inflammatory disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4048329